For health care professionals only

The information contained on this website is intended for use only by health care professionals in the United States. Countries outside of the United States may have different regulatory requirements or medical practices than the United States. Therefore, this information may not be appropriate for use outside of the United States.

Are you a health care professional in the United States?

You will now be leaving the NovoSeven^® RT website.

• HOME
• + RAPID BLEED CONTROL
• + RAPID ADMINISTRATION
• + SAFETY
• + NOVOSEVEN^® RT USES
• RESOURCES
• LIFE WITH INHIBITORS
• FULL PRESCRIBING
  INFORMATION
• FOR HEALTH CARE PROFESSIONALS

Share

Please see important safety information at the end of the page.

Models throughout are used for illustrative purposes only.

Indications and Usage

NovoSeven^® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

Important Safety Information

Warning: Serious thrombotic side effects are associated with the use of NovoSeven^® RT outside of the uses approved by the FDA. These thrombotic side effects are blood clots that form in arteries and veins and can cause harm and may lead to death. Your doctor should discuss the risks and explain the signs and symptoms of thrombotic side effects to you. Your doctor should monitor you for blood clots during treatment with NovoSeven^® RT.

Thrombotic side effects following the use of NovoSeven^® RT occurred in 0.28% of all bleeds that were treated for FDA-approved uses. The rate of 0.20% was observed in hemophilia patients with inhibitors, and the rate was higher in patients with acquired hemophilia (4%). Thrombotic events (fatal and non-fatal) have been reported following use of NovoSeven^® RT for all FDA-approved uses.

Some patients have conditions that may increase the risk of thrombotic side effects. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury (called disseminated intravascular coagulation), a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they are taking NovoSeven^® RT may be at increased risk for thrombotic side effects. NovoSeven^® RT should be used with caution in patients who have an increased risk for thrombotic side effects. These include, but are not limited to, patients with a history of heart disease, liver disease, patients who have limited movement following surgery, elderly patients, and neonates (babies who are 4 weeks old or younger). In each of these situations, the potential benefit of treatment with NovoSeven^® RT should be weighed against the risk of these complications.

Some patients with Factor VII deficiency have developed resistance (antibodies) to Factor VII after treatment with NovoSeven^® RT. Factor VII-deficient patients should be monitored for antibody formation before and after administration of NovoSeven^® RT.

People who have ever had a bad reaction to NovoSeven^® RT or to proteins from mice, hamsters, or “bovines” (such as an ox or cow) should consult their physician prior to using NovoSeven^® RT.

The most common side effects during clinical trials in people taking NovoSeven^® RT were fever, bleeding, injection site reaction, joint pain, headache, high or low blood pressure, nausea, vomiting, pain, swelling, and rash.

Please click here for NovoSeven^® RT Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

NovoSeven^® RT is a prescription medicine.

Novo Nordisk Inc., 100 College Road West, Princeton, New Jersey 08540 U.S.A.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven^® is a registered trademark of Novo Nordisk Health Care AG.
© 2011 Novo Nordisk     1210-00001368-1     April 2011